Engro & Associates

Market access leadership for a fraction of the commitment.

Launches are won or lost on market access. Pricing, coverage, channel, and coding decisions all get made years before a market access leader is ever in the room. I have led the market access strategy behind product launches in six therapeutic areas, three of which became blockbusters, and I now bring that judgment to companies on a fractional or interim basis.

Pharmaceutical, biotech, and drug-device combination product companies — whether that's 12–36 months from launch, or a seat that's open right now.

Book a 25-minute call →

Who I help

Three situations this practice was built to solve.

Pre-commercial biotech

  • Building market access for the first time, 12–36 months before launch
  • No market access function in place yet

Read the full guide →

Drug-device combination product companies

  • Coverage, coding, and payment strategy
  • Pre-approval market access planning

Commercial organizations

  • Interim Cover for an open VP, Director, or Head of Market Access role
  • Ongoing Leadership for a specific launch or asset

See how this works →

The cost of an empty seat

Market access work doesn't pause just because the seat is empty, or because no one has hired into the role yet. The position may have never existed, may have sat unfilled, or may have come open unexpectedly mid-launch. Either way, the only way to get senior market access judgment has usually been to have someone actually in the role, and the gap is what costs companies.

The missWhy it happensWhat it costs
Net price lands below the model Price set before anyone tested willingness to pay, benefit design or channel mix. Up to 20% of forecast revenue
Coverage arrives late Utilization management and formulary timing assumed rather than benchmarked against precedent. A year of revenue, unrecoverable
Wrong benefit or coding path Coding, coverage and payment treated as one decision instead of three. 3× regional variation in payment

None of it is recoverable later. A fractional arrangement costs a fraction of a fully loaded executive, and closes an open seat far faster than a search would — either way, closing the gap almost always costs less than leaving it open.

Most companies have already made their most important market access decisions, without realizing it →

How I can help, for a fraction of the commitment

These are the areas market access is responsible for in a launch. I can take on all of them, or only the ones you are not already covering.

Market access strategy and launch readiness

Payer value proposition, coverage precedent and utilization management benchmarks, indication sequencing, evidence planning, and the milestone plan from pre-approval engagement through first fill.

Pricing, contracting and gross-to-net

Price corridor development, gross-to-net architecture and stress testing, rebate and contracting strategy, government pricing exposure, and pricing governance.

Drug-device combination products and SaMD

Coding, coverage and payment treated as three separate decisions. Category I and III pathways, Medicare contractor coverage, site-of-care economics, and products with no established benefit category.

Channel and reimbursement operations

Specialty pharmacy and distribution network design, buy-and-bill, patient support hub build and vendor selection, affordability programs, and provider reimbursement support.

Team, vendors and governance

Standing up the market access function: role definition and hiring profiles, vendor selection and oversight, board and executive reporting, and handover to the permanent hire.

Payer research and field training

Primary research with current medical and pharmacy directors, competitive market access monitoring, and reimbursement training for field and commercial teams.

How engagements can work

Assessment

Four to six weeks

A fixed-scope review of your pricing assumptions, likely coverage, and evidence gaps — ending in a ranked list of what could go wrong and a ninety-day plan. Most engagements begin here.

Ongoing leadership

One to two days a week

I hold the market access seat: strategy, payer and pricing decisions, vendor oversight, and reporting into whoever owns commercialization or market access.

Interim cover

Three to nine months

Near-full-time coverage of an open market access role — through a launch, a leadership gap, or a sudden vacancy — until the permanent hire is in place.

Areas of expertise

Pharmacy benefit, medical benefit, and the channel underneath both. Most market access careers cover one of the three.

Rare and orphan disease

Four ultra-orphan therapies, two of them priced among the highest in the U.S. market — no comparator and no precedent to lean on.

Oncology, immunology and hematology

New-to-market launches across six therapeutic areas, three of which reached blockbuster status. Oral and infused, both benefits.

Drug-device combination products and SaMD

Ophthalmic and combination products, plus pre-approval market access strategy for a Class I Software as a Medical Device.

Specialty channel

First-ever patient support hubs built at two manufacturers, alongside specialty pharmacy and direct distribution networks.

Bill Engro

Experience

More than twenty-five years across large pharmaceutical, biotech and medical device manufacturers — entirely on the manufacturer side. I have owned this strategy from inside companies rather than advising on it from outside, so what I recommend is something a company can actually approve, fund and execute.

10+new-to-market launches
3reached blockbuster status
6therapeutic areas, pharmacy and medical benefit

Launch figures reflect products supported in senior market access roles at pharmaceutical, biotech and medical device manufacturers.

Questions clients ask first

Before booking a call, this is usually what people want to know.

Do you work with early-stage startups, or only larger organizations?

Both — that's the range I built this practice around. I've stood up market access strategy from scratch at emerging companies, and led it inside large, matrixed pharma organizations. What changes is the engagement model, not the fit: Assessment or Ongoing Leadership for a company building the function for the first time, Interim Cover for a larger organization filling a gap mid-stream — either way, it's built to sit inside whatever structure already exists, including your current vendors and agency partners.

Will you work with a company that competes with one of your clients?

No. I take one active client per therapeutic area or mechanism of action at a time, with NDA and exclusivity terms set at the contract level before an engagement begins.

What does this typically cost?

Pricing follows scope and time commitment. The Assessment is a fixed fee based on your asset pipeline. Ongoing Leadership and Interim Cover run on a monthly retainer or day rate, scoped and agreed before work starts.

Where are you based, and do you work remotely?

Based in the Chicago area, working remotely as a default. On-site travel — for board presentations, launch weeks, or key payer strategy sessions — can be built into the statement of work.

How does this work from a budget standpoint?

You engage me directly as an independent consultant — a statement of work and an invoiced fee, not a headcount addition. For organizations managing a hiring freeze or an approval delay, that typically makes it a consulting expense rather than an FTE hire.

What if our team is already fully staffed — can we bring you in just for your experience with a specific launch?

Yes. Not every engagement means an open seat. Some companies bring me in because I've already run a launch like theirs — a particular modality, a rare disease indication, a device with no established benefit category — and want that experience applied to their specific asset, working alongside the team already in place rather than in place of anyone.

Contact

Whether you're building the market access function for the first time, filling an open seat, or want a second opinion on a specific launch, I am glad to talk it through — three ways to reach me:

Bill Engro, Founder & Principal

Email bill.engro@engroassociates.com
Phone (224) 600-8054
Book a 25-minute call →